Sickle cell anemia as a possible state of enhanced anti-apoptotic tone: Survival effect of vascular endothelial growth factor on circulating and unanchored endothelial cells

Blood

Volumn 93, Issue 11, 1999, Pages 3824-3830

  Solovey, Anna ^b   Gui, Lizhen ^b   Ramakrishnan, Sundaram ^b   Steinberg, Martin H ^b   Hebbel, Robert P ^a  

^a UNIV OF MINNESOTA HOSP AND CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; APOPTOSIS; ARTICLE; CELL SURVIVAL; CLINICAL ARTICLE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RETINA NEOVASCULARIZATION; SICKLE CELL ANEMIA; VASCULAR ENDOTHELIUM;

EID: 0033152361     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.11.3824     Document Type: Article

References (48)

1. Majno G, Joris I: Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol 146:3, 1995
2. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1:27, 1995
3. Wright HP: Mitosis patterns in aortic endothelium. Atherosclerosis 15:93, 1972
4. Colville-Nash PR, Willoughby D: Growth factors in angiogenesis: Current interest and therapeutic potential. Mol Med Today 1:14, 1997
5. Battegay EJ: Angiogenesis: Mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med 73:333, 1995
6. Klagsbrun M, Soker S: VEGF/VPF: The angiogenesis factor found? Recent evidence suggests that vascular endothelial growth factor/vascular permeability factor may be the best candidate for the principal regulator of normal and tumor angiogenesis. Curr Biol 3:699, 1993
7. Auerbach W, Auerbach R: Angiogenesis inhibition: A review. Pharmacol Ther 63:265, 1994
8. Polunovsky VA, Wendt CH, Ingbar DH, Peterson MS, Bitterman PB: Induction of endothelial cell apoptosis by TNFα: Modulation by inhibitors of protein synthesis. Exp Cell Res 214:584, 1994
9. Spyridopoulos I, Brogi E, Kearney M, Sullivan AB, Cetrulo C, Isner JM, Losordo DW: Vascular endothelial growth factor inhibits endothelial cell apoptosis induced by tumor necrosis factor-α: Balance between growth and death signals. J Mol Cell Cardiol 29:1321, 1997
10. Araki S, Shimada Y, Kaji K, Hayashi H: Apoptosis of vascular endothelial cells by fibroblast growth factor deprivation. Biochem Biophys Res Commun 168:1194, 1990
11. Meredith JE Jr, Fazeli B, Schwartz MA: The extracellular matrix as a cell survival factor. Mol Biol Cell 4:953, 1993
12. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157, 1994
13. Re F, Zanetti A, Sironi M, Polentarutti N, Lanfrancone L, Dejana E, Colotta F: Inhibition of anchorage-dependent cell spreading triggers apoptosis in cultured human endothelial cells. J Cell Biol 127:537, 1994
14. Fuks Z, Persaud RS, Alfieri A, McLoughlin M, Ehleiter D, Schwartz JL, Seddon AP, Cordon-Cardo C, Haimovitz-Friedman A: Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res 54:2582, 1994
15. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E: Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1:1024, 1995
16. Watanabe Y, Dvorak HF: Vascular permeability factor/vascular endothelial growth factor inhibits anchorage-disruption-induced apoptosis in microvessel endothelial cells by inducing scaffold formation. Exp Cell Res 233:340, 1997
17. Kroll J, Waltenberger J: The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem 272:32521, 1997
18. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg M: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270:1326, 1995
19. Gupta K, Kshirsagar S, Li W, Gui L, Ramakrishnan S, Gupta P, Law PY, Hebbel RP: VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res (in press)
20. Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP: Circulating activated endothelial cells in sickle cell anemia. N Engl J Med 337:1584, 1997
21. Mohanraj D, Olson T, Ramakrishnan S: Expression of biologically active human vascular endothelial growth factor in yeast. Growth Factors 12:17, 1995
22. Gavrieli X, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493, 1992
23. Darzynkiewicz Z, Juan G, Li X, Gorczyca W, Murakami T, Traganos F: Cytometry in cell necrobiology: Analysis of apoptosis and accidental cell death (necrosis). Cytometry 27:1, 1997
24. Gupta K, Ramakrishnan S, Browne PV, Solovey A, Hebbel RP: A novel technique for culture of human dermal microvascular endothelial cells under either serum-free or serum-supplemented conditions: Isolation by panning and stimulation with vascular endothelial growth factor. Exp Cell Res 230:244, 1997
25. Kupfermine MJ, Daniel Y, Englender T, Baram A, Many A, Jaffa AJ, Gull I, Lessing JB: Vascular endothelial growth factor is increased in patients with preeclampsia, Am J Reprod Immunol 38:302, 1997
26. Wasada T, Kawahara R, Katsumori K, Naruse M, Omori Y: Plasma concentration of immunoreactive vascular endothelial growth factor and its relation to smoking. Metabolism 47:27, 1998
27. Lutty GA, Goldberg MF: Ophthalmologic complications, in Embury SH, Hebbel RP, Mohandas N, Steinberg MH (eds): Sickle Cell Disease, Basic Principles and Clinical Practice. New York, NY, Raven, 1994, p 703
28. Browne PV, Hebbel RP: Disturbance of plasma and platelet thrombospondin levels in sickle cell disease. Am J Hematol 51:296, 1996
29. Senger DR, Ledbetter SR, Claffey KP, Papadopoulos-Sergiou A, Perruzzi CA, Detmar M: Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the αvβ3 integrin, osteopontin, and thrombin. Am J Pathol 149:293, 1996
30. Francis RB, Haywood HJ: Elevated plasma tumor necrosis factor-alpha in sickle cell disease. J Natl Med Assoc 84:611, 1992
31. Guo N, Kurtzsch HC, Inman JK, Roberts DD: Thrombospondin 1 and type 1 repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res 57:1735, 1997
32. Gui CY, Jiang C, Xie HY, Qian RL: The apoptosis of HEL cells induced by hydroxyurea. Cell Res 7:91, 1997
33. Forsythe JA, Jiang B-H, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604, 1996
34. Stone J, Itin A, Alon T, Pe'er J, Gnessin H, Chan-Ling T, Keshet E: Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 15:4738, 1995
35. Waltenberger J, Mayr U, Pentz S, Hombach V: Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia. Circulation 94:1647, 1996
36. Brogi E, Schatteman G, Wu T, Kim EA, Varticovski L, Keyt B, Isner JM: Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. J Clin Invest 97:469, 1996
37. Cao J, Kunz M, Merges C, McLeod DS, Lutty GA: Immunolocalization of angiogenic factors in proliferative sickle cell retinopathy. Sickle Cell Disease in the 21st Century. Proceedings of the National Sickle Cell Disease Conference, Washington, DC, September 15-20, 1997
38. Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E: Upregulated expression of vascular endothelial growth factor in proliferative diabetic retinopathy. Br J Ophthalmol 80:241, 1996
39. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV, Aiello LM, Ferrara N, King GL: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480, 1994
40. Embury SH, Hebbel RP, Steinberg MH, Mohandas N: Pathogenesis of Vasoocclusion, in Embury SH, Hebbel RP, Mohandas N, Steinberg MH (eds): Sickle Cell Disease, Basic Principles and Clinical Practice. New York, NY, Raven, 1994, p 311
41. Akinola NO, Stevens SME, Franklin IM, Nash GB, Stuart J: Subdinical ischaemic episodes during the steady state of sickle cell anemia. J Clin Pathol 45:902, 1992
42. Hebbel RP, Solovey AA, Solovey AN: Circulating endothelial cells (CEC) have the same activation phenotype as vessel wall endothelium in sickle transgenic mice. Experimental Biology '99, Washington, DC, April 1999 (abstr) (submitted)
43. Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C, Kearney M, Chen D, Chen D, Symes JF, Fishman MC, Huang PL, Isner JM: Nitroic oxidize synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 101:2567, 1998
44. Shen BQ, Lee DY, Zioncheck TF: Vascular endothelial growth factor (VEGF) increases endothelial nitric oxide synthase (eNOS) activity and expression via a KDR receptor signaling pathway. Mol Biol Cell 9:113a, 1998 (abstr, suppl)
45. Nath KA, Smith LA, Croatt AJ, Haggard JJ, Hebbel RP, Katusic ZS: Abnormal vascular behavior in a model of sickle cell disease. J Am Soc Nephr 9: A1748, 1998 (abstr)
46. Kaul DK, Liu XC, Fabry ME, Nagel RL: Increased nitric oxide synthase expression in transgenic sickle mouse is associated with relative hypotension and altered microvascular responses. Blood 92: 330a, 1998 (abstr, suppl 1)
47. Johnson CS, Giorgio AJ: Arterial blood pressure in adults with sickle cell disease. Arch Intern Med 141:891, 1981
48. Hatch FE, Crowe LR, Miles DE, Young JP, Portner ME: Altered vascular reactivity in sickle hemoglobinopathy: A possible protective factor from hypertension. Am J Hypertension 2:2, 1989